Breast cancer or the threat of it is a reality in too many women’s lives, including that of the actress Angelina Jolie as we learned earlier this month. As women mull their options for genetic testing, screening and treatment for the disease, one factor that can loom large is the extent to which their health insurance will cover whatever choices they make.
Most coverage is pretty good, experts agree, and it's getting better under the Affordable Care Act. Still, there are weak spots, and some plans are woefully inadequate. In those instances, a woman may face high out-of-pocket costs or have to appeal plan denials to get the coverage she needs.
Jolie announced that she underwent genetic testing and, after learning she has a genetic mutation that significantly increases her risk of breast and ovarian cancers, had a double mastectomy. Her mother died of ovarian cancer at age 56.
Read the full story here: http://bit.ly/18nMtba
Source: Kaiser Health News
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More